At the 2019 ESC congress in Paris, AstraZeneca presented full results from the Phase III DAPA-HF trial studying type 2 diabetes drug Farxiga in HFrEF. The drug showed great promise...
4 September 2019 Analysis
2 September 2019 News
Novartis has announced that its heart failure with reduced ejection fraction (HFrEF) drug Entresto (sacubitril/valsartan) has shown further efficacy in two Phase IV trials, PROVE-HF and EVALUATE-HF.
22 August 2019 Comment
GlobalData believes a decision for an AdCom to be held does not translate negatively to the drug’s chances for a successful FDA label expansion.
20 August 2019 News
AstraZeneca has announced that Farxiga (dapagliflozin) met its primary endpoint in heart failure-focused Phase III DAPA-HF trial of patients with reduced ejection fraction (HFrEF).
19 August 2019 News
Researchers from Virginia Tech University (VT) have developed a variant of the compound alphaCT1, which can improve heart attack recovery if administered during, or soon after, a heart attack.
18 July 2019 Comment
Forxiga is indicated for monotherapy and combination therapy use to improve glycemic control with the additional benefits of weight loss and blood pressure reduction.
17 June 2019 Comment
Amarin’s Vascepa, AstraZeneca’s Epanova theoretical cardiovascular risk reduction class effect possibly stifled
Although Amarin’s Vascepa (icosapent ethyl) is likely to lock in US Food and Drug Administration approval and swift uptake in cardiovascular disease (CVD) risk reduction, there could be future competition...
23 April 2019 pressreleases
Creative Pharma Services attended the Hellenic Society for Pharmaceutical Management on 18 April.